샘플 요청 목록

 카트 문의
시장보고서
상품코드
1797347

세계의 신장암 치료 및 진단 시장

Kidney Cancer Therapeutics and Diagnostics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 299 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

신장암 치료 및 진단 세계 시장은 2030년까지 79억 달러에 달할 전망

2024년에 67억 달러로 추정되는 신장암 치료 및 진단 세계 시장은 2024-2030년 분석 기간 동안 CAGR 2.7%로 성장하여 2030년에는 79억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 투명세포 RCC 암은 CAGR 2.7%를 기록하며 분석 기간 종료까지 22억 달러에 달할 것으로 예측됩니다. 유두상 RCC 암 부문의 성장률은 분석 기간 동안 CAGR 2.1%로 추정됩니다.

미국 시장은 18억 달러로 추정, 중국은 CAGR 5.1%로 성장 예측

미국의 신장암 치료 및 진단 시장은 2024년에 18억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 15억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 5.1%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 1.0%와 2.0%로 예측됩니다. 유럽에서는 독일이 CAGR 1.5%로 성장할 것으로 예측됩니다.

세계의 신장암 치료 및 진단 시장 - 주요 동향과 촉진요인 정리

신장암이 암 치료에서 전략적 중요성이 높아지는 이유는 무엇일까?

신장암은 전 세계적으로 유병률 증가, 복잡한 분자 병인학, 다양한 치료법 스펙트럼으로 인해 종양학 치료의 초점으로 부상하고 있습니다. 신세포암(RCC)은 신장 악성 종양의 약 85-90%를 차지하며, 특히 고소득 국가에서는 이환율과 사망률이 모두 증가하고 있습니다. 이 질환은 기존 화학요법에 내성을 보이기 때문에 표적 치료제, 면역관문억제제, 개인별 맞춤 분자 프로파일링으로 치료의 축을 옮기고 있습니다. 그 결과, 주요 바이오기업들은 혁신적인 작용기전, 바이오마커 기반 치료, 면역요법과 티로신 키나아제 억제제(TKI)의 병용요법에 투자하며 치료 패러다임을 근본적으로 재편하고 있습니다.

영상 진단과 분자진단의 기술적 발전은 특히 흡연자, 비만인, 신장암 가족력이 있는 고위험군의 신장암 조기발견과 위험도 분류를 재정의하고 있습니다. 다중 파라미터 MRI, PET 기반 추적자, 새로운 순환 종양 DNA(ctDNA) 분석은 비침습적 진단 및 모니터링 도구로 임상적 지지를 받고 있습니다. 그 결과, 진단의 정확도가 향상되어 종양 전문의가 질병 진행 초기에 표적 치료를 시행할 수 있게 되었습니다. 한편, 방사선 의학에서 인공지능의 통합은 임상의가 신장 종괴의 양성과 악성을 더 높은 민감도로 구별하는 데 도움이 되고 있으며, 치료 계획과 결과 예측에 직접적인 영향을 미치고 있습니다.

면역종양학과 정밀의학으로 치료 알고리즘은 어떻게 진화하고 있는가?

전이성 RCC의 최전선 치료제로 등장한 면역관문억제제(ICI)의 도입으로 신장암 치료의 틀이 빠르게 진화하고 있습니다. 니볼루맙+이필리무맙, 펨브롤리주맙+악시티닙 등의 병용요법은 현재 표준요법으로 여겨지고 있으며, 여러 임상시험에서 생존기간의 유의미한 연장이 입증되었습니다. 이러한 발전은 단일 약물 접근법에서 혈관내피성장인자(VEGF) 경로를 표적으로 하면서 면역회피 메커니즘을 조절하도록 설계된 복합 프로토콜로의 전환을 강조하고 있습니다. 저산소 유도 인자 2α&(HIF-2α&)와 MET 억제제를 표적으로 하는 몇몇 신약도 후기 임상시험 단계에 있으며, 치료 툴박스를 더욱 확대하고자 합니다.

맞춤형 의료는 신장암 치료제 개발 및 임상시험 설계에 점점 더 많은 영향을 미치고 있습니다. 차세대 염기서열분석(NGS) 플랫폼은 드라이버 돌연변이 및 실용적인 바이오마커를 식별하는 데 사용되며, 정밀한 치료 할당 및 적응증별 투여 요법을 가능하게 합니다. 또한, 관찰 등록 및 종단적 데이터 플랫폼에서 얻은 실제 증거는 치료 순서와 독성 관리를 개선하는 데 도움이 되고 있으며, 새로운 치료법은 효과뿐만 아니라 내구성 및 QOL을 통해 평가되고 있습니다. 이러한 환자 중심의 생물학적 치료로의 전환은 시장의 경쟁 역학을 재정의하고 있으며, 생명공학 혁신기업과 제약사들은 효능과 개별화 적용 가능성을 통해 제품 차별화를 꾀하고 있습니다.

진단 혁신과 바이오마커 전략은 시장 확대에 어떤 역할을 할 것인가?

진단학의 발전은 조기 발견, 더 나은 병기 결정, 치료 효과의 동적 모니터링을 가능하게함으로써 신장암 시장 확대에 매우 중요한 역할을 하고 있습니다. 특히 ctDNA, 무세포 DNA, 엑솜 RNA를 측정하는 액체 생검 플랫폼은 비침습적 감시 및 잔존 병변 추적을 위해 채택되고 있습니다. 이러한 분석은 특히 전이성 질환에서 병의 진행과 치료 저항성을 예측하는 데 유용하다는 것이 입증되고 있습니다. 또한, 단백질체학 및 대사체학 프로파일링이 진단 워크플로우에 통합되어 특이성을 향상시키고 적절한 치료 경로를 위해 환자를 계층화합니다.

방사성동위원소 및 AI 기반 영상 분석은 CT 및 MRI 스캔에서 종양의 공격성 및 면역치료 반응성과 상관관계가 있는 정량적 특징을 추출하여 신장암 진단에 혁명을 일으키고 있습니다. 기계학습 알고리즘은 병리학적 아형, 혈관 신생 수준, 면역학적 마커를 예측하기 위해 대규모 영상 데이터세트로 훈련되어 영상의학과 전문의와 종양 전문의에게 의사결정 지원 도구를 제공합니다. 한편, 진단 시약 및 플랫폼 제조업체들은 RCC에 특화된 다중 면역조직화학(IHC) 키트와 NGS 패널에 대한 수요 증가를 목격하고 있습니다. 이러한 플랫폼은 임상 및 중개연구의 요구를 지원하며, 연구기관의 구매 및 실험실 개발 시험(LDT) 승인을 촉진하고 있습니다.

또한, 환자 옹호 및 인식 개선 캠페인은 진단을 널리 알리는 데 일조하고 있습니다. 검진율이 낮은 지역에서는 국가 암 대책 계획에 RCC에 초점을 맞춘 인식 제고, 검진, 조기 개입 정책이 포함되고 있습니다. 이러한 공중 보건 대책은 분자진단에 대한 보험 적용률 증가와 함께 암 진단 연구소의 환자 처리 능력에 긍정적인 영향을 미치고 있습니다. 시장이 성숙해짐에 따라 진단기술의 크로스 라이선스 및 제약사와 진단약사의 동반진단(CDx) 제휴가 급증하고, 치료와 진단의 긴밀한 연계가 가능해져 대응 가능한 환자군이 확대될 것으로 예상됩니다.

세계 각 지역의 시장 성장을 이끄는 요인은 무엇인가?

세계 신장암 치료 및 진단 시장의 성장은 신장 악성 종양 발생률 증가, 치료 혁신의 확대, 정밀 진단에 대한 접근성 확대 등 여러 요인에 의해 주도되고 있습니다. 북미, 유럽, 중국, 인도 등 신흥 시장에서는 비만, 고혈압, 흡연율 증가로 인해 RCC의 역학적 부담이 증가하고 있습니다. 이러한 발병률의 증가는 치료 시작률의 증가와 고급 진단 약품에 대한 광범위한 수요로 이어지고 있습니다. 또한, 인구의 고령화와 의료 인프라의 개선으로 이전에는 충분한 서비스를 받을 수 없었던 지역에서도 암 진단을 쉽게 이용할 수 있게 되었습니다.

정부의 자금 지원과 유리한 약사법으로 인해 새로운 치료제와 진단약의 임상 연구, 신속한 승인 및 상환이 가속화되고 있습니다. FDA, EMA 등의 기관은 유망한 신장암 치료제에 대해 획기적 치료제로 지정하거나 조건부 승인을 통해 혁신적인 후보물질의 시장 출시 시간을 단축하고 있습니다. 또한, 학계, 산업계, 공중보건기관이 참여하는 다자간 협력은 세계 임상시험 네트워크를 강화하여 다양한 환자 코호트 등록을 용이하게 하고, 강력한 임상 증거를 생성할 수 있도록 돕고 있습니다.

상업적 측면에서는 표적 치료제 맞춤형 CDx 솔루션을 공동 개발하기 위한 제약회사와 진단회사들의 전략적 제휴가 시장에 이익을 가져다주고 있습니다. PD-L1 발현, MET 변화, 혈관신생 바이오마커를 확인하는 동반진단은 환자를 특정 치료 요법에 맞게 계층화하여 임상적 결과와 지불자의 수용성을 높이는 데 도움이 됩니다. 또한, 특히 북미와 아시아태평양에서는 환자가 원격지에서 분자 프로파일링 서비스에 접근할 수 있도록 하는 DTC 검사 및 원격 종양학 플랫폼이 파괴적인 힘으로 부상하고 있습니다. 이러한 역학을 종합하면, 신장암 치료 및 진단 시장은 향후 10년간 혁신에 기반한 지속적인 성장을 이룰 것으로 예상됩니다.

부문

암종(투명세포 RCC 암, 유두상 RCC 암, 크롬포브세포 RCC 암, 요로상피암/전이세포암, 윌름스 종양 암, 신장육종 암, 수집관 RCC 암, 기타 신장암), 진단(생검 진단, 영상 검사 진단, 혈액 검사 진단, 기타 진단)

조사 대상 기업 사례

  • AstraZeneca plc
  • Bayer AG
  • BeiGene Ltd.
  • Bristol-Myers Squibb
  • Caris Life Sciences
  • Cigna Healthcare
  • Clovis Oncology
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genentech
  • GlaxoSmithKline plc(GSK)
  • Illumina, Inc.
  • Ipsen
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Promega Corporation
  • Siemens Healthineers
  • Thermo Fisher Scientific

AI 통합

우리는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.09.03

Global Kidney Cancer Therapeutics and Diagnostics Market to Reach US$7.9 Billion by 2030

The global market for Kidney Cancer Therapeutics and Diagnostics estimated at US$6.7 Billion in the year 2024, is expected to reach US$7.9 Billion by 2030, growing at a CAGR of 2.7% over the analysis period 2024-2030. Clear Cell RCC Cancer, one of the segments analyzed in the report, is expected to record a 2.7% CAGR and reach US$2.2 Billion by the end of the analysis period. Growth in the Papillary RCC Cancer segment is estimated at 2.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.8 Billion While China is Forecast to Grow at 5.1% CAGR

The Kidney Cancer Therapeutics and Diagnostics market in the U.S. is estimated at US$1.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.5 Billion by the year 2030 trailing a CAGR of 5.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 2.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.

Global Kidney Cancer Therapeutics And Diagnostics Market - Key Trends & Drivers Summarized

Why Is Kidney Cancer Gaining Strategic Significance in Oncology Therapeutics?

Kidney cancer is emerging as a focal point within the oncology therapeutics landscape due to its increasing global prevalence, complex molecular etiology, and expanding spectrum of treatment modalities. Renal cell carcinoma (RCC) constitutes approximately 85-90% of all kidney malignancies and has demonstrated both rising incidence and mortality rates, particularly in high-income nations. The disease's resistance to traditional chemotherapies has prompted a therapeutic pivot toward targeted therapies, immune checkpoint inhibitors, and personalized molecular profiling. Consequently, major biopharma companies are investing in innovative mechanisms of action, biomarker-driven treatments, and combinations of immunotherapy and tyrosine kinase inhibitors (TKIs), fundamentally reshaping the therapeutic paradigm.

Technological advances in imaging and molecular diagnostics are redefining the early detection and risk stratification of kidney cancer, particularly among high-risk groups such as smokers, obese individuals, and those with a family history of renal malignancy. Multiparametric MRI, PET-based tracers, and novel circulating tumor DNA (ctDNA) assays are gaining clinical traction as non-invasive diagnostic and monitoring tools. As a result, diagnostic precision is improving, allowing oncologists to deploy targeted therapies earlier in the disease progression. Meanwhile, the integration of artificial intelligence in radiology is helping clinicians distinguish between benign and malignant renal masses with greater sensitivity, directly impacting treatment planning and outcome forecasting.

How Are Treatment Algorithms Evolving Through Immuno-Oncology and Precision Medicine?

The therapeutic framework for kidney cancer is rapidly evolving through the incorporation of immune checkpoint inhibitors (ICIs), which have emerged as frontline treatments for metastatic RCC. Combinations such as nivolumab plus ipilimumab or pembrolizumab plus axitinib are now considered gold standard regimens, with multiple studies demonstrating significant survival benefits. These advances underscore the transition from single-agent approaches to combinatorial protocols designed to modulate immune evasion mechanisms while targeting vascular endothelial growth factor (VEGF) pathways. Several novel agents targeting hypoxia-inducible factor 2 alpha (HIF-2α) and MET inhibitors are also in late-stage clinical trials, aiming to further expand the therapeutic toolbox.

Personalized medicine is increasingly influencing drug development and clinical trial design in kidney cancer. Next-generation sequencing (NGS) platforms are being used to identify driver mutations and actionable biomarkers, enabling precision treatment allocation and adaptive dosing regimens. Furthermore, real-world evidence from observational registries and longitudinal data platforms is helping refine treatment sequencing and toxicity management, ensuring that emerging therapies are evaluated not only by efficacy but also by durability and quality of life. This shift toward patient-centered, biology-driven care is redefining the competitive dynamics of the market, as biotech innovators and pharmaceutical giants seek to differentiate their offerings through both efficacy and personalized applicability.

What Role Do Diagnostic Innovations and Biomarker Strategies Play in Market Expansion?

Advancements in diagnostics are playing a pivotal role in kidney cancer market expansion by enabling earlier detection, better staging, and dynamic monitoring of treatment response. Liquid biopsy platforms, particularly those measuring ctDNA, cell-free DNA, and exosomal RNA, are increasingly adopted for non-invasive surveillance and residual disease tracking. These assays are proving valuable in predicting disease progression and therapeutic resistance, especially in the metastatic setting. Additionally, proteomic and metabolomic profiling are being integrated into diagnostic workflows to improve specificity and stratify patients for appropriate therapeutic pathways.

Radiomics and AI-driven imaging analytics are revolutionizing kidney cancer diagnostics by extracting quantitative features from CT and MRI scans that correlate with tumor aggressiveness and immunotherapy responsiveness. Machine learning algorithms are being trained on large image datasets to predict pathological subtypes, angiogenesis levels, and immunological markers-thus offering decision-support tools for radiologists and oncologists. Meanwhile, diagnostic reagent and platform manufacturers are witnessing increased demand for multiplex immunohistochemistry (IHC) kits and NGS panels specific to RCC. These platforms support clinical and translational research needs, driving institutional purchases and lab-developed test (LDT) approvals.

Moreover, patient advocacy and awareness campaigns are playing a role in increasing diagnostic uptake. In regions with under-screened populations, national cancer control plans are now incorporating RCC-focused awareness, screening, and early intervention policies. These public health measures, combined with rising insurance coverage for molecular diagnostics, are positively influencing patient throughput in cancer diagnostic labs. As the market matures, cross-licensing of diagnostic technologies and companion diagnostic (CDx) partnerships between pharma and diagnostic companies are expected to surge, enabling tighter therapeutic-diagnostic alignment and expanding addressable patient populations.

What Factors Are Driving Market Growth Across Global Regions?

The growth in the global kidney cancer therapeutics and diagnostics market is driven by several factors, including the increasing incidence of renal malignancies, expanding therapeutic innovations, and growing access to precision diagnostics. The epidemiological burden of RCC is intensifying in North America, Europe, and emerging markets like China and India due to rising obesity, hypertension, and smoking prevalence. This rising incidence is translating into higher treatment initiation rates and broader demand for advanced diagnostics. Moreover, aging populations and improved healthcare infrastructure are making cancer diagnostics more accessible in previously underserved regions.

Government funding initiatives and favorable regulatory pathways are accelerating clinical research, fast-track approvals, and reimbursement coverage for novel therapies and diagnostics. Agencies such as the FDA and EMA are providing breakthrough therapy designations and conditional approvals for promising therapies in kidney cancer, shortening time-to-market for innovative candidates. Furthermore, multi-stakeholder collaborations involving academic institutions, industry, and public health bodies are strengthening global trial networks and facilitating the enrollment of diverse patient cohorts, thereby supporting robust clinical evidence generation.

On the commercial side, the market is benefiting from strategic alliances between pharmaceutical and diagnostic companies to co-develop CDx solutions tailored to targeted therapies. Companion diagnostics that identify PD-L1 expression, MET alterations, or angiogenesis biomarkers are helping stratify patients for specific therapeutic regimens, enhancing clinical outcomes and payer acceptance. Additionally, direct-to-consumer testing and tele-oncology platforms are emerging as disruptive forces, particularly in North America and Asia-Pacific, enabling patients to access molecular profiling services remotely. Collectively, these dynamics are positioning the kidney cancer therapeutics and diagnostics market for sustained, innovation-led growth over the next decade.

SCOPE OF STUDY:

The report analyzes the Kidney Cancer Therapeutics and Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Cancer Type (Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer, Other Kidney Cancers); Diagnostics (Biopsy Diagnostics, Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • AstraZeneca plc
  • Bayer AG
  • BeiGene Ltd.
  • Bristol-Myers Squibb
  • Caris Life Sciences
  • Cigna Healthcare
  • Clovis Oncology
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genentech
  • GlaxoSmithKline plc (GSK)
  • Illumina, Inc.
  • Ipsen
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Promega Corporation
  • Siemens Healthineers
  • Thermo Fisher Scientific

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Kidney Cancer Therapeutics and Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Renal Cell Carcinoma Throws the Spotlight on Early Detection Technologies
    • Advancements in Immuno-Oncology Therapies Propel Growth in Targeted Kidney Cancer Treatments
    • Growing Adoption of Liquid Biopsies Expands Diagnostic Accuracy and Market Scope
    • FDA Approvals for Novel Drug Combinations Strengthen Business Case for First-Line Therapies
    • Patient Stratification via Genomic Profiling Drives Adoption of Precision Therapeutics
    • Expansion of Cancer Screening Programs in Developing Economies Generates Demand for Diagnostic Kits
    • Emergence of Companion Diagnostics Spurs Integration of Therapeutics and Testing Platforms
    • Shift Toward Minimally Invasive Biopsy Procedures Accelerates Market Penetration
    • Growing Clinical Pipeline of VEGF and mTOR Inhibitors Fuels Therapeutic Innovation
    • Increasing Investment in Cancer Immunotherapy Expands Addressable Market Opportunity
    • Rising Awareness of Kidney Health in Aging Populations Sustains Demand for Screening Solutions
    • Strategic Collaborations Between Pharma and Diagnostic Firms Drive Technology Integration
    • Reimbursement Reforms for Oncology Care Strengthen Access to Premium Diagnostics and Drugs
    • Integration of AI in Radiological Imaging Enhances Detection and Monitoring of Renal Tumors
    • Rising Use of Biomarkers for Recurrence Prediction Spurs R&D in Molecular Diagnostics
    • Hospital Infrastructure Modernization Drives Adoption of Advanced Diagnostic Equipment
    • Regulatory Fast-Track Approvals Propel Commercialization of Promising Therapeutics
    • Global Focus on Personalized Oncology Care Catalyzes Adoption of Genomics-Based Therapies
    • Challenges in Drug Pricing and Access Pose Barriers to Widespread Therapeutic Uptake
    • Expansion of Cancer Registries and Databases Bolsters Data-Driven R&D in Kidney Cancer
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Kidney Cancer Therapeutics and Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Kidney Cancer Therapeutics and Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Clear Cell RCC Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Clear Cell RCC Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Clear Cell RCC Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Papillary RCC Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Papillary RCC Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Papillary RCC Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Chromophobe RCC Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Chromophobe RCC Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Chromophobe RCC Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Urothelial Carcinoma / Transitional Cell Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Urothelial Carcinoma / Transitional Cell Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Urothelial Carcinoma / Transitional Cell Carcinoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Wilms Tumor Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Wilms Tumor Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Wilms Tumor Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Renal Sarcoma Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Renal Sarcoma Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Renal Sarcoma Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Collecting Duct RCC Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Collecting Duct RCC Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Collecting Duct RCC Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Kidney Cancers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Kidney Cancers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Other Kidney Cancers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Imaging Tests Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Imaging Tests Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Imaging Tests Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Blood Tests Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Blood Tests Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Blood Tests Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Other Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Other Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Other Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Biopsy Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Biopsy Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Biopsy Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Kidney Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
  • JAPAN
    • Kidney Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
  • CHINA
    • Kidney Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: China 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: China 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
  • EUROPE
    • Kidney Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Kidney Cancer Therapeutics and Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
  • FRANCE
    • Kidney Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: France 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
    • TABLE 77: France Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: France 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
  • GERMANY
    • Kidney Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Germany Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Germany 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
    • TABLE 83: Germany Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Germany Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Germany 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 86: Italy Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Italy Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Italy 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
    • TABLE 89: Italy Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Italy Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Italy 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Kidney Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 92: UK Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: UK Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: UK 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
    • TABLE 95: UK Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: UK Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: UK 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 98: Spain Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Spain Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Spain 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
    • TABLE 101: Spain Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Spain Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Spain 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 104: Russia Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Russia Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Russia 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
    • TABLE 107: Russia Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Russia Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Russia 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of Europe Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Rest of Europe 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
    • TABLE 113: Rest of Europe Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Rest of Europe Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Rest of Europe 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Kidney Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific Historic Review for Kidney Cancer Therapeutics and Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Asia-Pacific 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 119: Asia-Pacific Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Asia-Pacific Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: Asia-Pacific 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
    • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Asia-Pacific Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Asia-Pacific 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Kidney Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 125: Australia Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Australia Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Australia 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
    • TABLE 128: Australia Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Australia Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Australia 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
  • INDIA
    • Kidney Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 131: India Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: India Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: India 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
    • TABLE 134: India Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: India Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: India 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 137: South Korea Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: South Korea Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: South Korea 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
    • TABLE 140: South Korea Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: South Korea Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: South Korea 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 143: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Asia-Pacific Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Rest of Asia-Pacific 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
    • TABLE 146: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Asia-Pacific Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Rest of Asia-Pacific 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Kidney Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 149: Latin America Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 150: Latin America Historic Review for Kidney Cancer Therapeutics and Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Latin America 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 152: Latin America Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Latin America Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Latin America 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
    • TABLE 155: Latin America Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Latin America Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Latin America 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 158: Argentina Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Argentina Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Argentina 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
    • TABLE 161: Argentina Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Argentina Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Argentina 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 164: Brazil Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Brazil Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Brazil 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
    • TABLE 167: Brazil Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Brazil Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Brazil 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 170: Mexico Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Mexico Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Mexico 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
    • TABLE 173: Mexico Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Mexico Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Mexico 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 176: Rest of Latin America Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Rest of Latin America Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Rest of Latin America 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
    • TABLE 179: Rest of Latin America Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Latin America Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Rest of Latin America 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Kidney Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 182: Middle East Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 183: Middle East Historic Review for Kidney Cancer Therapeutics and Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Middle East 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 185: Middle East Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Middle East Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Middle East 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
    • TABLE 188: Middle East Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Middle East Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Middle East 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 191: Iran Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Iran Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Iran 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
    • TABLE 194: Iran Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Iran Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Iran 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 197: Israel Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Israel Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Israel 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
    • TABLE 200: Israel Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Israel Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Israel 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 203: Saudi Arabia Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Saudi Arabia Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Saudi Arabia 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
    • TABLE 206: Saudi Arabia Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Saudi Arabia Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Saudi Arabia 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 209: UAE Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: UAE Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: UAE 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
    • TABLE 212: UAE Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: UAE Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: UAE 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 215: Rest of Middle East Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Rest of Middle East Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: Rest of Middle East 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
    • TABLE 218: Rest of Middle East Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Rest of Middle East Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 220: Rest of Middle East 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
  • AFRICA
    • Kidney Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 221: Africa Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Africa Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 223: Africa 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
    • TABLE 224: Africa Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Africa Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 226: Africa 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제